

Table SIV. Changes in atopic dermatitis-associated parameters after 16 weeks dupilumab treatment in patients according to clinical findings

Outcome	Clinical findings	Coefficient	95% CI	p-value
Total EASI	General type	-1.38	-1.59, -1.16	<0.001
	Facial type	-1.06	-1.38, -0.75	<0.001
	Prurigo type	-1.05	-1.22, -0.87	<0.001
HN-EASI	General type	-0.14	-0.17, -0.12	<0.001
	Facial type	-0.06	-0.09, -0.02	0.003
	Prurigo type	-0.11	-0.14, -0.09	<0.001
POEM	General type	-0.74	-0.86, -0.63	<0.001
	Facial type	-0.78	-0.97, -0.59	<0.001
	Prurigo type	-0.69	-0.85, -0.52	<0.001
I-NRS	General type	-0.26	-0.31, -0.21	<0.001
	Facial type	-0.38	-0.49, -0.26	<0.001
	Prurigo type	-0.22	-0.30, -0.14	<0.001

95% CI: 95% confidence interval; EASI: Eczema Area and Severity Index; HN-EASI: Head and Neck Eczema Area and Severity Index; POEM: Patient-Oriented Eczema Measure; I-NRS: Itch Numerical Rating Scale.